La Jolla Pharmaceutical Receivables

La Jolla Pharmaceutical (LJPC) currently reports a receivables of $5.9M as of June 2022. That compares with $12M in the prior-year period — down 50.5% year over year. Use the charts on this page to explore La Jolla Pharmaceutical's receivables history and peer comparisons.

La Jolla Pharmaceutical's receivables decreased from $12M to $5.9M — a 50.5% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

La Jolla Pharmaceutical reported $5.9M in receivables as of June 2022. That compares with $12M in the prior-year period — down 50.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $5.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for La Jolla Pharmaceutical, and consider following LJPC for alerts when major investors trade the stock.

La Jolla Pharmaceutical is classified in the Healthcare sector. On receivables, it currently shows $5.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LJPC with unrelated industries.